By Phillip Lanos, business podcast host Episode recorded , for Entrepreneur's Action & Ambition podcast.
TL;DR / Key takeaways
- Arjan Haverhals joined Milestone Scientific in June 2020, in the middle of the pandemic, after 14 years in a large corporate role, because he believed in the technology and, above all, in the company's founder.
- Milestone's stated ambition is to become the standard of care in anesthesia, replacing a hypodermic syringe design he dates to 1860 with computer controlled injection technology.
- Its dynamic pressure sensing technology controls the flow of an injection by measuring pressure at the tip of the needle, delivering local anesthetic slowly enough to stay below the patient's pain threshold.
- And it turns out that in epidural procedures, the same technology shifts from injecting a drug to verifying needle placement, and he says it can cut a training curve of up to two years and 100 procedures down to two days and two procedures.
- So his leadership rule is to ask for the story behind the number before managing the number itself, and to build a culture where people laugh, own their work, and are allowed to make mistakes.
About the guest
Arjan Haverhals is the president of Milestone Scientific, a medical technology company built around computer controlled injection systems, and he's served as president and chief executive officer of its dental division, Wand Dental Inc., since June 2020. He took the Milestone president role in September 2020. Born and raised in the Netherlands, he studied pharmacy in Leiden because he wanted to understand what a drug does inside the human body, and he's spent more than 30 years in sales, marketing, product development, and international expansion across the medical device and pharmaceutical industries, living abroad for most of that career. Before Milestone, he spent 14 years with Straumann in Switzerland, a leader in implant dentistry. Scale and savings figures in this article are the figures he stated on the episode, at the time of recording in December 2021.
Episode summary
Arjan's career started with a scientific itch: not prescribing a drug for a headache, but understanding what the drug does inside the body to relieve it. Pharmacy studies in Leiden led to a pharmaceutical company in the Netherlands, an invitation to the head offices in Oslo after three years, and a three decade international career. After 14 years in a large corporate environment at Straumann, he wanted a smaller organization where he could build a team directly and carry end responsibility for the business. He joined Milestone Scientific in June 2020, recruited for the dental division, without expecting the role to grow the way it did. He's candid about the deciding factor: respect for the company's founder, who was then interim CEO, accounted for more than 95 percent of his reason for joining.
Well, it turns out the company he joined was shifting from a research and development identity into commercialization. Its founding insight is that drug delivery is still dominated by a syringe invented in 1860. Milestone's dynamic pressure sensing technology measures pressure changes at the tip of the needle and controls the flow of the injection, so local anesthetic is delivered slowly, below the patient's pain threshold. In dentistry that means a virtually painless injection without the hours of numb lips and cheeks patients expect. In medicine, applied to epidurals during labor and delivery, the same core technology verifies needle placement instead, and Arjan argues the economics, the training time, and the patient risk all move with it.
Key insights
Ask for the story behind the number
Arjan manages cash, profit, and shareholder value, and he says so plainly. But his first question is narrative, not numerical: what's the story behind the number, and how does it point to where the company should be in three to five years? He pairs that with a Dutch habit he describes with a smile: deep pockets, and flipping a coin not twice but three or four times before investing it. Discipline and story, in his telling, aren't opposites. And it turns out the story is what tells you which numbers deserve discipline and which deserve investment.
Set the ambition at standard of care level
His vision for Milestone is stated in one line: take drug delivery from the 1900s into the 21st century, and become the standard of care in anesthesia. The competitive framing is what makes the ambition concrete. And it turns out the rival product isn't another device company. It's the hypodermic syringe, a design from 1860 still in daily use in an era when everything else in the procedure room is digital. Naming an outdated default as the competition clarifies the size of the opening.
Painless is a technology specification, not a promise
About 40 million people in the United States are dental phobic, in his telling, and the injection is a big part of that fear. So Milestone's answer is engineering, not reassurance. Dynamic pressure sensing measures pressure changes and pressure output at the tip of the needle, and the system administers the anesthetic slowly, at a controlled flow, so it can't be injected above the patient's pain threshold. The result he describes is an injection that's virtually painless, with fewer of the familiar side effects: no numb lips and cheeks for three or four hours afterward. He points to more than 100 publications using the technology in dental, and singles out pediatric dentistry, where fear of the needle is the whole appointment.
The same technology does a different job in medicine
Moving from dental to medical changed what the technology is for. In dental, the system injects the drug. In epidural analgesia during labor and delivery, it verifies needle placement. The stakes he cites are punctures that can result in migraine, paralysis, or even mortality, and a manual technique, loss of resistance, that can take a resident up to two years and 100 procedures to master. With Milestone's technology, he says, that becomes two days and two procedures, which is why teaching institutions matter to the company's education strategy. So the technology doesn't replace the clinician. It shortens the road to proficiency and gives experienced clinicians a verification tool.
The economics have to close for the hospital
Arjan makes the hospital's case in the hospital's language. He cites independent studies in epidural analgesia concluding that savings of $504 per average patient hospital stay could be obtained, which scales to about $6 million at a hospital performing 12,000 epidural procedures. He adds the cost of litigation, which he estimates at about $300,000 on average. Those figures sit alongside the market he's aiming at: at the time of recording he put the addressable market in epidural analgesia at about $5 billion, with about 11 million procedures in the United States and 30 million worldwide, including 2.4 million epidurals out of about 4 million United States births a year. Clinical benefit opens the conversation. And it turns out documented savings are what he expects to close it.
Build a culture where mistakes are allowed and owned
Everyone on his team wears two to three hats, so his culture rules are practical. He wants an environment where it's fun to work, where people laugh, where mistakes are allowed, and where everyone helps the next person, provided people are transparent and flag problems early. And it turns out the people in the organization come first, in his account, and that includes his own maintenance: family time with his wife and daughters, running and other sports, and playing the piano are how he recharges the battery in hours rather than waiting for a two week holiday. His underlying optimism is a stated operating principle: every problem can be solved, and the more complex the problem, the more interest he's got in it.
Notable quotes
"What is the story behind the number?"
"Taking drug delivery of the 1900s to the 21st century, because our competition in the marketplace is the hypodermic syringe that was invented in 1860."
"We really believe that we can become the standard of care in anesthesia."
"In life I've learned that every problem can be solved."
"I want to have an environment where it is fun to work in, where people laugh, where mistakes are allowed."
Phillip's Take: The story behind the number is the strategy
What stayed with me from Arjan is a sentence most finance conversations never produce. He has to manage cash, profit, and shareholder value, and he said so. But his first question is what the story behind the number is. That ordering matters. A scientist who became a chief executive is telling you the number is evidence, not the decision. The decision comes from understanding what produced the number and where it points three to five years out.
Across the interviews I've hosted, the operators who last tend to work in that order. They respect the bottom line without worshipping it. Arjan flips the coin three or four times before he spends it, which is discipline. But he flipped his whole career, leaving 14 comfortable corporate years in the middle of a pandemic, because he believed a founder's story about a better technology. That's judgment about a story, made by a man who reads numbers for a living.
The lesson I would hand a founder is this. Learn to tell the story behind your numbers before someone asks. Investors, partners, and teams don't just fund results. They fund a credible explanation of how the results happened and why they will keep happening. If you can't narrate your own numbers, somebody else will narrate them for you, and you may not like their version.
FAQ
What does Milestone Scientific make?
Computer controlled injection technology built on dynamic pressure sensing, which measures pressure at the tip of the needle and controls the flow of an injection. It began in dentistry, delivering local anesthetic slowly enough to stay below the patient's pain threshold, and has expanded into medical uses including epidural procedures.
How does the technology make a dental injection virtually painless?
Instead of one shot of local anesthetic from a conventional syringe, the system administers the drug slowly at a controlled speed, guided by pressure changes at the needle tip. Because the anesthetic stays below the patient's pain threshold, Arjan describes the injection as virtually painless, without the hours of numb lips and cheeks that follow a conventional injection.
Why did Arjan Haverhals join Milestone Scientific?
He wanted to move from a large corporate environment back to a smaller organization where he could build a team and carry end responsibility. He believed in the technology and its commercial potential, and he says respect for the company's founder, then its interim CEO, was more than 95 percent of his reason for joining in June 2020.
What is different about the technology's medical use?
In dental, the system injects the drug. In epidural analgesia during labor and delivery, it verifies needle placement. He says it can reduce the time to proficiency with a difficult manual technique from up to two years and 100 procedures to two days and two procedures, and he cites documented savings of $504 per average patient hospital stay.
How does Arjan Haverhals lead through hard days?
He starts from a stated belief that every problem can be solved, and he protects the inputs that keep him steady: family, running and sport, and playing the piano, recharging in hours rather than waiting for a long holiday. So inside the company, his answer is cultural: people first, ownership, transparency, and an environment where mistakes are allowed and discussed.
Who would Arjan Haverhals invite to dinner, dead or alive?
Nelson Mandela. He points to what Mandela went through, his vision, and the leadership he gave a country in difficulty after coming out of prison. His closing thought is equality: that we're all equal, independent of age, gender, or race, and should treat people with respect and include them.
About the host / book this show
Phillip Lanos is a business podcast host and author. Over 13 years he's hosted 1,000+ interviews with founders, executives, and operators (1,000+ interviews hosted, the reconciled sitewide count), including about 500 episodes of Entrepreneur's Action & Ambition, plus work for Inc., EO, Al Jazeera, and Grit Daily. His shows are conversational founder interviews for entrepreneurs, startups, and the operators building them, and every featured conversation becomes a permanent, structured article on this site.
For PR agencies and publicists: this is a business podcast built for founder and executive guests who can tell their own story. Booking route: the consultation contact on this site, phillip@philliplanos.com. No email address is published here by design; use the contact page so requests are tracked.
Originally recorded for Entrepreneur's Action & Ambition. This article is an original summary and analysis of that conversation, published on Phillip Lanos's own site.
Related episodes
Aaron Speach on Bringing the Bet to Where Fans Already Watch
Ada Hu on Rebuilding a Marketing Agency After Revenue Fell 99 Percent
Adriana Monique Alvarez on Writing the Book Before You Market It
More interviews: Leadership topic hub · All articles